New daily pill shows promise in early breast cancer trial
NCT ID NCT03850873
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new daily pill called TQB3616 in 40 adults with advanced breast cancer that had stopped responding to standard hormone therapy. The pill works by blocking a protein that helps cancer cells multiply. The main goals were to find a safe dose and understand how the body processes the drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fifth Medical Center of Chinese People's Liberation Army General Hospital
Beijing, Beijing Municipality, 100039, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 45008, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 212028, China
-
The Fourth Hospital of Hebei Medical University and Hebei
Shijiazhuang, Hebei, 050011, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
- Can a pill combo outpace chemotherapy for aggressive breast cancer?
- Blood tests could reveal hidden resistance in breast cancer
- Triple threat: three new targeted drugs join forces with immunotherapy to attack Hard-to-Treat breast cancer
- New drug sequence aims to outsmart advanced breast cancer
- Could a pill replace an IV for advanced breast cancer treatment?